To include your compound in the COVID-19 Resource Center, submit it here.

Tumor Targeted Superantigens: Phase IIa

In an ongoing, open-label U.K. Phase IIa study, preliminary data showed

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE